Market Cap | 78.06M | P/E | - | EPS this Y | 62.80% | Ern Qtrly Grth | - |
Income | -131.56M | Forward P/E | -0.79 | EPS next Y | -29.60% | 50D Avg Chg | 11.00% |
Sales | 4.15M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | 0.72 | EPS next 5Y | - | 52W High Chg | -66.00% |
Recommedations | 2.00 | Quick Ratio | 3.22 | Shares Outstanding | 26.81M | 52W Low Chg | 57.00% |
Insider Own | 1.32% | ROA | -51.11% | Shares Float | 13.94M | Beta | 1.58 |
Inst Own | 81.10% | ROE | -393.39% | Shares Shorted/Prior | 1.10M/1.24M | Price | 3.79 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 74,632 | Target Price | 11.00 |
Oper. Margin | -2,835.00% | Earnings Date | Nov 12 | Volume | 39,194 | Change | -3.81% |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Piper Sandler | Overweight | Aug 13, 24 |
JMP Securities | Market Outperform | Aug 13, 24 |
HC Wainwright & Co. | Buy | Aug 13, 24 |
HC Wainwright & Co. | Buy | Aug 1, 24 |
HC Wainwright & Co. | Buy | Jun 26, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Piper Sandler | Overweight | Apr 3, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
Piper Sandler | Overweight | Oct 3, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
AKKARAJU SRINIVAS | Director Director | Dec 21 | Buy | 4.42 | 904,977 | 3,999,998 | 1,786,427 | 12/26/23 |
Olson Eric R | Chief Scientific Off.. Chief Scientific Officer | Jul 17 | Sell | 3.50 | 689 | 2,412 | 6,661 | 07/18/23 |
Young Richard A | Director Director | Feb 10 | Sell | 8.87 | 5,990 | 53,131 | 329,211 | 02/10/21 |
Simonian Nancy A | President & CEO President & CEO | Dec 21 | Option | 7.21 | 29,917 | 215,702 | 563,606 | 12/21/20 |
Young Richard A | Director Director | Nov 18 | Sell | 8.87 | 5,990 | 53,131 | 339,211 | 11/18/20 |